Vasiliki Michalarea

Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma

Lewis Au, Emine Hatipoglu, Marc Robert de Massy et al. · Cancer Cell · 2021 · 256 citations · Full text

Life Sciences, Immunology, Oncology +17

Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i> - and Non– <i>BRCA1/2</i> -Mutant Cancers

Timothy A. Yap, Rebecca Kristeleit, Vasiliki Michalarea et al. · Cancer Discovery · 2020 · 134 citations · Full text

Medicine, Oncology, Pharmacology +13

A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer

Michael Kolinsky, Pasquale Rescigno, Diletta Bianchini et al. · Annals of Oncology · 2020 · 88 citations · Full text

Medicine, Oncology, Pharmacology +17

The neutrophil–lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials

Rajiv Kumar, Elena Geuna, Vasiliki Michalarea et al. · British Journal of Cancer · 2015 · 80 citations · Full text

Medicine, Immunology, Oncology +14

Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue

Kevin Litchfield, Stacey Stanislaw, Lavinia Spain et al. · Cell Reports · 2020 · 77 citations · Full text

Medicine, Cancer Biology, Oncology +17